69 citations
,
December 2005 in “Nature Clinical Practice Endocrinology & Metabolism” Blocking the enzyme 11β-HSD1 might help treat obesity and metabolic issues.
20 citations
,
June 2022 in “Molecules” This review discusses three classes of thiazole-bearing compounds in drug development and presents preclinical findings but reports no new experimental results, highlighting the need for further drug discovery.
70 citations
,
March 2010 in “The Journal of Steroid Biochemistry and Molecular Biology” This study discusses the potential of targeting 11β-HSD1 for treating metabolic syndrome and highlights emerging promising data from human trials on selective 11β-HSD1 inhibitors.
54 citations
,
December 2007 in “Best Practice & Research Clinical Endocrinology & Metabolism” This review discusses the potential of targeting glucocorticoid action as a treatment strategy for obesity and type-2 diabetes, highlighting promising animal study results but reports no new clinical findings.
43 citations
,
August 2010 in “Expert Opinion on Investigational Drugs” This review explores the potential of selective 11β-HSD1 inhibitors to improve insulin sensitivity in type 2 diabetes, emphasizing the need for more clinical research and reports no new clinical results.